Zentalis Pharmaceuticals, Inc. - 8-K Filing

Zentalis Pharmaceuticals reports Q3 2026 results with $228.9 million in cash providing runway into 1H 2028. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ZNTL

Read the full article at SEC EDGAR

Part of the story Cencora, Inc. - 8-K Filing (3 articles)

More Regulatory news